nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0288	0.15	CbGbCtD
Crizotinib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0247	0.129	CbGbCtD
Crizotinib—ABCB1—Betamethasone—ankylosing spondylitis	0.0161	0.084	CbGbCtD
Crizotinib—ABCB1—Prednisolone—ankylosing spondylitis	0.0159	0.0828	CbGbCtD
Crizotinib—BMP2K—synovial membrane of synovial joint—ankylosing spondylitis	0.0157	0.105	CbGeAlD
Crizotinib—RIPK2—synovial membrane of synovial joint—ankylosing spondylitis	0.0151	0.101	CbGeAlD
Crizotinib—ABCB1—Prednisone—ankylosing spondylitis	0.015	0.0782	CbGbCtD
Crizotinib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0148	0.0774	CbGbCtD
Crizotinib—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0144	0.075	CbGbCtD
Crizotinib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0112	0.0586	CbGbCtD
Crizotinib—ROS1—tendon—ankylosing spondylitis	0.00964	0.0644	CbGeAlD
Crizotinib—CYP3A4—Betamethasone—ankylosing spondylitis	0.00964	0.0503	CbGbCtD
Crizotinib—CYP3A4—Prednisolone—ankylosing spondylitis	0.00951	0.0496	CbGbCtD
Crizotinib—ABCB1—Dexamethasone—ankylosing spondylitis	0.00936	0.0488	CbGbCtD
Crizotinib—CYP3A4—Prednisone—ankylosing spondylitis	0.00898	0.0469	CbGbCtD
Crizotinib—MUSK—tendon—ankylosing spondylitis	0.0082	0.0548	CbGeAlD
Crizotinib—ABCB1—Methotrexate—ankylosing spondylitis	0.00752	0.0392	CbGbCtD
Crizotinib—Vitreous floaters—Betamethasone—ankylosing spondylitis	0.00659	0.0357	CcSEcCtD
Crizotinib—Vitreous floaters—Dexamethasone—ankylosing spondylitis	0.00659	0.0357	CcSEcCtD
Crizotinib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00561	0.0293	CbGbCtD
Crizotinib—Photopsia—Dexamethasone—ankylosing spondylitis	0.0047	0.0255	CcSEcCtD
Crizotinib—Photopsia—Betamethasone—ankylosing spondylitis	0.0047	0.0255	CcSEcCtD
Crizotinib—LIMK1—tendon—ankylosing spondylitis	0.00431	0.0288	CbGeAlD
Crizotinib—MAPK7—tendon—ankylosing spondylitis	0.00388	0.0259	CbGeAlD
Crizotinib—FES—tendon—ankylosing spondylitis	0.00384	0.0257	CbGeAlD
Crizotinib—MET—tendon—ankylosing spondylitis	0.00363	0.0243	CbGeAlD
Crizotinib—TAOK2—tendon—ankylosing spondylitis	0.00348	0.0233	CbGeAlD
Crizotinib—DCLK1—tendon—ankylosing spondylitis	0.00318	0.0213	CbGeAlD
Crizotinib—FER—tendon—ankylosing spondylitis	0.00297	0.0198	CbGeAlD
Crizotinib—TNK1—tendon—ankylosing spondylitis	0.00294	0.0196	CbGeAlD
Crizotinib—MAP4K1—tendon—ankylosing spondylitis	0.00291	0.0194	CbGeAlD
Crizotinib—MAP4K2—tendon—ankylosing spondylitis	0.00281	0.0188	CbGeAlD
Crizotinib—STK3—tendon—ankylosing spondylitis	0.00277	0.0185	CbGeAlD
Crizotinib—AURKA—tendon—ankylosing spondylitis	0.0027	0.0181	CbGeAlD
Crizotinib—TESK1—tendon—ankylosing spondylitis	0.00268	0.0179	CbGeAlD
Crizotinib—MERTK—tendon—ankylosing spondylitis	0.00261	0.0174	CbGeAlD
Crizotinib—Lymphopenia—Prednisone—ankylosing spondylitis	0.00255	0.0138	CcSEcCtD
Crizotinib—ACVR1—tendon—ankylosing spondylitis	0.00252	0.0169	CbGeAlD
Crizotinib—MAP3K12—tendon—ankylosing spondylitis	0.00252	0.0169	CbGeAlD
Crizotinib—Visual acuity reduced—Betamethasone—ankylosing spondylitis	0.00252	0.0136	CcSEcCtD
Crizotinib—Visual acuity reduced—Dexamethasone—ankylosing spondylitis	0.00252	0.0136	CcSEcCtD
Crizotinib—STK35—tendon—ankylosing spondylitis	0.00247	0.0165	CbGeAlD
Crizotinib—ABL2—tendon—ankylosing spondylitis	0.00241	0.0161	CbGeAlD
Crizotinib—BMP2K—tendon—ankylosing spondylitis	0.00238	0.0159	CbGeAlD
Crizotinib—PTK2B—tendon—ankylosing spondylitis	0.0023	0.0154	CbGeAlD
Crizotinib—RIPK2—tendon—ankylosing spondylitis	0.00228	0.0152	CbGeAlD
Crizotinib—Abscess—Prednisolone—ankylosing spondylitis	0.00227	0.0123	CcSEcCtD
Crizotinib—EPHA4—tendon—ankylosing spondylitis	0.0022	0.0147	CbGeAlD
Crizotinib—Febrile neutropenia—Prednisone—ankylosing spondylitis	0.00217	0.0117	CcSEcCtD
Crizotinib—TBK1—tendon—ankylosing spondylitis	0.00212	0.0142	CbGeAlD
Crizotinib—PTK2—tendon—ankylosing spondylitis	0.00212	0.0142	CbGeAlD
Crizotinib—TYK2—tendon—ankylosing spondylitis	0.0021	0.0141	CbGeAlD
Crizotinib—Abscess—Triamcinolone—ankylosing spondylitis	0.00208	0.0113	CcSEcCtD
Crizotinib—Abscess—Methylprednisolone—ankylosing spondylitis	0.00208	0.0113	CcSEcCtD
Crizotinib—IRAK1—tendon—ankylosing spondylitis	0.00208	0.0139	CbGeAlD
Crizotinib—RPS6KB1—tendon—ankylosing spondylitis	0.00204	0.0136	CbGeAlD
Crizotinib—FGR—tendon—ankylosing spondylitis	0.00202	0.0135	CbGeAlD
Crizotinib—AXL—tendon—ankylosing spondylitis	0.00202	0.0135	CbGeAlD
Crizotinib—SLK—tendon—ankylosing spondylitis	0.00194	0.013	CbGeAlD
Crizotinib—EPHB4—tendon—ankylosing spondylitis	0.00193	0.0129	CbGeAlD
Crizotinib—JAK2—tendon—ankylosing spondylitis	0.00191	0.0128	CbGeAlD
Crizotinib—Abscess—Betamethasone—ankylosing spondylitis	0.00189	0.0102	CcSEcCtD
Crizotinib—Abscess—Dexamethasone—ankylosing spondylitis	0.00189	0.0102	CcSEcCtD
Crizotinib—EPHA2—tendon—ankylosing spondylitis	0.00189	0.0126	CbGeAlD
Crizotinib—MAP4K5—tendon—ankylosing spondylitis	0.00184	0.0123	CbGeAlD
Crizotinib—MAP3K3—tendon—ankylosing spondylitis	0.00184	0.0123	CbGeAlD
Crizotinib—TEK—tendon—ankylosing spondylitis	0.00184	0.0123	CbGeAlD
Crizotinib—Febrile neutropenia—Methotrexate—ankylosing spondylitis	0.00181	0.0098	CcSEcCtD
Crizotinib—EPHB6—tendon—ankylosing spondylitis	0.00176	0.0118	CbGeAlD
Crizotinib—YES1—tendon—ankylosing spondylitis	0.0017	0.0114	CbGeAlD
Crizotinib—Fluid retention—Prednisolone—ankylosing spondylitis	0.0017	0.00922	CcSEcCtD
Crizotinib—STK10—tendon—ankylosing spondylitis	0.00169	0.0113	CbGeAlD
Crizotinib—Neuropathy—Prednisolone—ankylosing spondylitis	0.00168	0.00912	CcSEcCtD
Crizotinib—TAOK3—tendon—ankylosing spondylitis	0.00168	0.0112	CbGeAlD
Crizotinib—Abscess—Prednisone—ankylosing spondylitis	0.00165	0.00892	CcSEcCtD
Crizotinib—Burning sensation—Methotrexate—ankylosing spondylitis	0.00157	0.00849	CcSEcCtD
Crizotinib—Fluid retention—Triamcinolone—ankylosing spondylitis	0.00157	0.00848	CcSEcCtD
Crizotinib—Fluid retention—Methylprednisolone—ankylosing spondylitis	0.00156	0.00846	CcSEcCtD
Crizotinib—Neuropathy—Triamcinolone—ankylosing spondylitis	0.00155	0.00838	CcSEcCtD
Crizotinib—Neuropathy—Methylprednisolone—ankylosing spondylitis	0.00154	0.00836	CcSEcCtD
Crizotinib—Interstitial lung disease—Methotrexate—ankylosing spondylitis	0.00154	0.00833	CcSEcCtD
Crizotinib—CSF1R—tendon—ankylosing spondylitis	0.00147	0.00983	CbGeAlD
Crizotinib—Fluid retention—Betamethasone—ankylosing spondylitis	0.00142	0.00769	CcSEcCtD
Crizotinib—Fluid retention—Dexamethasone—ankylosing spondylitis	0.00142	0.00769	CcSEcCtD
Crizotinib—Hepatotoxicity—Methotrexate—ankylosing spondylitis	0.00141	0.00764	CcSEcCtD
Crizotinib—Neuropathy—Dexamethasone—ankylosing spondylitis	0.0014	0.00761	CcSEcCtD
Crizotinib—Neuropathy—Betamethasone—ankylosing spondylitis	0.0014	0.00761	CcSEcCtD
Crizotinib—Abscess—Methotrexate—ankylosing spondylitis	0.00138	0.00745	CcSEcCtD
Crizotinib—Visual disturbance—Prednisolone—ankylosing spondylitis	0.00137	0.00744	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Methylprednisolone—ankylosing spondylitis	0.00137	0.00743	CcSEcCtD
Crizotinib—Fluid retention—Prednisone—ankylosing spondylitis	0.00124	0.0067	CcSEcCtD
Crizotinib—Neuropathy—Prednisone—ankylosing spondylitis	0.00122	0.00662	CcSEcCtD
Crizotinib—ABL1—tendon—ankylosing spondylitis	0.00116	0.00777	CbGeAlD
Crizotinib—Muscular weakness—Prednisolone—ankylosing spondylitis	0.00115	0.00622	CcSEcCtD
Crizotinib—Visual disturbance—Betamethasone—ankylosing spondylitis	0.00115	0.00621	CcSEcCtD
Crizotinib—Visual disturbance—Dexamethasone—ankylosing spondylitis	0.00115	0.00621	CcSEcCtD
Crizotinib—Sepsis—Prednisone—ankylosing spondylitis	0.00113	0.00612	CcSEcCtD
Crizotinib—Respiratory failure—Methotrexate—ankylosing spondylitis	0.00111	0.006	CcSEcCtD
Crizotinib—Pulmonary embolism—Methotrexate—ankylosing spondylitis	0.00109	0.0059	CcSEcCtD
Crizotinib—Muscular weakness—Triamcinolone—ankylosing spondylitis	0.00106	0.00572	CcSEcCtD
Crizotinib—Muscular weakness—Methylprednisolone—ankylosing spondylitis	0.00105	0.0057	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.00105	0.0057	CcSEcCtD
Crizotinib—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.000988	0.00535	CcSEcCtD
Crizotinib—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.000988	0.00535	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	0.000983	0.00532	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Triamcinolone—ankylosing spondylitis	0.000961	0.00521	CcSEcCtD
Crizotinib—Muscular weakness—Betamethasone—ankylosing spondylitis	0.000958	0.00519	CcSEcCtD
Crizotinib—Muscular weakness—Dexamethasone—ankylosing spondylitis	0.000958	0.00519	CcSEcCtD
Crizotinib—Sepsis—Methotrexate—ankylosing spondylitis	0.000945	0.00512	CcSEcCtD
Crizotinib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.00092	0.00498	CcSEcCtD
Crizotinib—Infestation—Methylprednisolone—ankylosing spondylitis	0.00092	0.00498	CcSEcCtD
Crizotinib—Bradycardia—Prednisolone—ankylosing spondylitis	0.000917	0.00496	CcSEcCtD
Crizotinib—Face oedema—Prednisone—ankylosing spondylitis	0.000913	0.00494	CcSEcCtD
Crizotinib—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	0.000904	0.0049	CcSEcCtD
Crizotinib—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	0.000902	0.00488	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.00089	0.064	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.00089	0.064	CbGdCrCtD
Crizotinib—Hepatic failure—Methotrexate—ankylosing spondylitis	0.000879	0.00476	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000876	0.063	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000876	0.063	CbGdCrCtD
Crizotinib—Visual impairment—Prednisolone—ankylosing spondylitis	0.000868	0.0047	CcSEcCtD
Crizotinib—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000861	0.00466	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000856	0.0616	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000856	0.0616	CbGdCrCtD
Crizotinib—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000849	0.0046	CcSEcCtD
Crizotinib—Weight decreased—Betamethasone—ankylosing spondylitis	0.000849	0.0046	CcSEcCtD
Crizotinib—Bradycardia—Triamcinolone—ankylosing spondylitis	0.000843	0.00456	CcSEcCtD
Crizotinib—Bradycardia—Methylprednisolone—ankylosing spondylitis	0.000841	0.00455	CcSEcCtD
Crizotinib—Muscular weakness—Prednisone—ankylosing spondylitis	0.000834	0.00452	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000834	0.00452	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—ankylosing spondylitis	0.000834	0.00452	CcSEcCtD
Crizotinib—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	0.00082	0.00444	CcSEcCtD
Crizotinib—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	0.00082	0.00444	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—ankylosing spondylitis	0.000812	0.0584	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—ankylosing spondylitis	0.000812	0.0584	CbGdCrCtD
Crizotinib—Arrhythmia—Prednisolone—ankylosing spondylitis	0.000804	0.00436	CcSEcCtD
Crizotinib—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.000796	0.00431	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—ankylosing spondylitis	0.000793	0.057	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000793	0.057	CbGdCrCtD
Crizotinib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000772	0.00418	CcSEcCtD
Crizotinib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000767	0.00415	CcSEcCtD
Crizotinib—Bradycardia—Betamethasone—ankylosing spondylitis	0.000765	0.00414	CcSEcCtD
Crizotinib—Bradycardia—Dexamethasone—ankylosing spondylitis	0.000765	0.00414	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—ankylosing spondylitis	0.000764	0.00414	CcSEcCtD
Crizotinib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000745	0.00403	CcSEcCtD
Crizotinib—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.00074	0.00401	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—ankylosing spondylitis	0.000739	0.004	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—ankylosing spondylitis	0.000739	0.004	CcSEcCtD
Crizotinib—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000738	0.004	CcSEcCtD
Crizotinib—Visual impairment—Betamethasone—ankylosing spondylitis	0.000724	0.00392	CcSEcCtD
Crizotinib—Visual impairment—Dexamethasone—ankylosing spondylitis	0.000724	0.00392	CcSEcCtD
Crizotinib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000719	0.00389	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000714	0.00387	CcSEcCtD
Crizotinib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000706	0.00382	CcSEcCtD
Crizotinib—Syncope—Prednisolone—ankylosing spondylitis	0.000703	0.00381	CcSEcCtD
Crizotinib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000702	0.0038	CcSEcCtD
Crizotinib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000702	0.0038	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000689	0.00373	CcSEcCtD
Crizotinib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000671	0.00363	CcSEcCtD
Crizotinib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000671	0.00363	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—ankylosing spondylitis	0.000666	0.00361	CcSEcCtD
Crizotinib—Syncope—Triamcinolone—ankylosing spondylitis	0.000646	0.0035	CcSEcCtD
Crizotinib—Syncope—Methylprednisolone—ankylosing spondylitis	0.000645	0.00349	CcSEcCtD
Crizotinib—Oedema—Prednisolone—ankylosing spondylitis	0.00064	0.00346	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000639	0.00346	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000635	0.00344	CcSEcCtD
Crizotinib—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000633	0.00343	CcSEcCtD
Crizotinib—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000632	0.00342	CcSEcCtD
Crizotinib—Shock—Prednisolone—ankylosing spondylitis	0.000629	0.00341	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000613	0.00332	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—ankylosing spondylitis	0.000611	0.00331	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000609	0.0033	CcSEcCtD
Crizotinib—Infestation—Methotrexate—ankylosing spondylitis	0.000609	0.0033	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000608	0.00329	CcSEcCtD
Crizotinib—Oedema—Triamcinolone—ankylosing spondylitis	0.000588	0.00319	CcSEcCtD
Crizotinib—Syncope—Dexamethasone—ankylosing spondylitis	0.000586	0.00318	CcSEcCtD
Crizotinib—Syncope—Betamethasone—ankylosing spondylitis	0.000586	0.00318	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000584	0.00317	CcSEcCtD
Crizotinib—Infection—Triamcinolone—ankylosing spondylitis	0.000584	0.00316	CcSEcCtD
Crizotinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000583	0.00316	CcSEcCtD
Crizotinib—Shock—Triamcinolone—ankylosing spondylitis	0.000579	0.00313	CcSEcCtD
Crizotinib—Shock—Methylprednisolone—ankylosing spondylitis	0.000577	0.00313	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000576	0.00312	CcSEcCtD
Crizotinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000576	0.00312	CcSEcCtD
Crizotinib—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000575	0.00311	CcSEcCtD
Crizotinib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000575	0.00311	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000574	0.00311	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000574	0.0413	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000574	0.0413	CbGdCrCtD
Crizotinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00057	0.00309	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—ankylosing spondylitis	0.00057	0.00308	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000565	0.0406	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000565	0.0406	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000552	0.0397	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000552	0.0397	CbGdCrCtD
Crizotinib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.00054	0.00292	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—ankylosing spondylitis	0.000537	0.00291	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000536	0.0029	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—ankylosing spondylitis	0.000534	0.00289	CcSEcCtD
Crizotinib—Oedema—Betamethasone—ankylosing spondylitis	0.000534	0.00289	CcSEcCtD
Crizotinib—Infection—Dexamethasone—ankylosing spondylitis	0.00053	0.00287	CcSEcCtD
Crizotinib—Infection—Betamethasone—ankylosing spondylitis	0.00053	0.00287	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000528	0.00286	CcSEcCtD
Crizotinib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000527	0.00285	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—ankylosing spondylitis	0.000527	0.00285	CcSEcCtD
Crizotinib—Anaemia—Prednisone—ankylosing spondylitis	0.000526	0.00285	CcSEcCtD
Crizotinib—Shock—Dexamethasone—ankylosing spondylitis	0.000525	0.00284	CcSEcCtD
Crizotinib—Shock—Betamethasone—ankylosing spondylitis	0.000525	0.00284	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000524	0.00284	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Prednisone—ankylosing spondylitis	0.000523	0.0377	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—ankylosing spondylitis	0.000523	0.0377	CbGdCrCtD
Crizotinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000523	0.00283	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000523	0.00283	CcSEcCtD
Crizotinib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000518	0.0028	CcSEcCtD
Crizotinib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000517	0.0028	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000511	0.00277	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000511	0.0368	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—ankylosing spondylitis	0.000511	0.0368	CbGdCrCtD
Crizotinib—Syncope—Prednisone—ankylosing spondylitis	0.000511	0.00277	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000507	0.00275	CcSEcCtD
Crizotinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000507	0.00275	CcSEcCtD
Crizotinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000506	0.00274	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000501	0.00271	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000493	0.00267	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000482	0.00261	CcSEcCtD
Crizotinib—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000479	0.0026	CcSEcCtD
Crizotinib—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000479	0.0026	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000476	0.00258	CcSEcCtD
Crizotinib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00047	0.00254	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00047	0.00254	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000466	0.00252	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000465	0.00252	CcSEcCtD
Crizotinib—Oedema—Prednisone—ankylosing spondylitis	0.000465	0.00252	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000464	0.00251	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000464	0.00251	CcSEcCtD
Crizotinib—Infection—Prednisone—ankylosing spondylitis	0.000462	0.0025	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000461	0.0025	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000461	0.0025	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—ankylosing spondylitis	0.00046	0.00249	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.00046	0.00249	CcSEcCtD
Crizotinib—Shock—Prednisone—ankylosing spondylitis	0.000457	0.00248	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000456	0.00247	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000451	0.00244	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000449	0.00243	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—ankylosing spondylitis	0.00044	0.00238	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000426	0.00231	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000423	0.00229	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000422	0.00229	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000422	0.00228	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000422	0.00228	CcSEcCtD
Crizotinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000421	0.00228	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—ankylosing spondylitis	0.000417	0.00226	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000409	0.00222	CcSEcCtD
Crizotinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000404	0.00219	CcSEcCtD
Crizotinib—Rash—Prednisolone—ankylosing spondylitis	0.000403	0.00218	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000403	0.00218	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000402	0.00218	CcSEcCtD
Crizotinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000402	0.00217	CcSEcCtD
Crizotinib—Fatigue—Prednisone—ankylosing spondylitis	0.000401	0.00217	CcSEcCtD
Crizotinib—Constipation—Prednisone—ankylosing spondylitis	0.000397	0.00215	CcSEcCtD
Crizotinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000389	0.00211	CcSEcCtD
Crizotinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000388	0.0021	CcSEcCtD
Crizotinib—Infection—Methotrexate—ankylosing spondylitis	0.000386	0.00209	CcSEcCtD
Crizotinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000383	0.00207	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000383	0.00207	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000381	0.00206	CcSEcCtD
Crizotinib—Nausea—Prednisolone—ankylosing spondylitis	0.00038	0.00206	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000377	0.00204	CcSEcCtD
Crizotinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000374	0.00203	CcSEcCtD
Crizotinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000373	0.00202	CcSEcCtD
Crizotinib—Rash—Triamcinolone—ankylosing spondylitis	0.000371	0.00201	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000371	0.00201	CcSEcCtD
Crizotinib—Rash—Methylprednisolone—ankylosing spondylitis	0.00037	0.002	CcSEcCtD
Crizotinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00037	0.002	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000367	0.00199	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000365	0.00198	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000365	0.00198	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000353	0.00191	CcSEcCtD
Crizotinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000353	0.00191	CcSEcCtD
Crizotinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000349	0.00189	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000349	0.00189	CcSEcCtD
Crizotinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000349	0.00189	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000346	0.00188	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000342	0.00185	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000339	0.00184	CcSEcCtD
Crizotinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000339	0.00184	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000338	0.00183	CcSEcCtD
Crizotinib—Rash—Dexamethasone—ankylosing spondylitis	0.000337	0.00182	CcSEcCtD
Crizotinib—Rash—Betamethasone—ankylosing spondylitis	0.000337	0.00182	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000336	0.00182	CcSEcCtD
Crizotinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000336	0.00182	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000335	0.00182	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000335	0.00181	CcSEcCtD
Crizotinib—Asthenia—Prednisone—ankylosing spondylitis	0.000333	0.00181	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000318	0.00172	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000317	0.00172	CcSEcCtD
Crizotinib—Nausea—Betamethasone—ankylosing spondylitis	0.000317	0.00172	CcSEcCtD
Crizotinib—Dizziness—Prednisone—ankylosing spondylitis	0.000307	0.00166	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000307	0.00166	CcSEcCtD
Crizotinib—Vomiting—Prednisone—ankylosing spondylitis	0.000296	0.0016	CcSEcCtD
Crizotinib—Rash—Prednisone—ankylosing spondylitis	0.000293	0.00159	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000293	0.00159	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000279	0.00151	CcSEcCtD
Crizotinib—Nausea—Prednisone—ankylosing spondylitis	0.000276	0.0015	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000266	0.00144	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—ankylosing spondylitis	0.000257	0.00139	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—ankylosing spondylitis	0.000247	0.00134	CcSEcCtD
Crizotinib—Rash—Methotrexate—ankylosing spondylitis	0.000245	0.00133	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000245	0.00133	CcSEcCtD
Crizotinib—Nausea—Methotrexate—ankylosing spondylitis	0.000231	0.00125	CcSEcCtD
Crizotinib—JAK3—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000122	0.000265	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—HLA-B—ankylosing spondylitis	0.00012	0.00026	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—CRP—ankylosing spondylitis	0.000119	0.000259	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—CRP—ankylosing spondylitis	0.000119	0.000259	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000119	0.000259	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000119	0.000259	CbGpPWpGaD
Crizotinib—FES—Developmental Biology—TNF—ankylosing spondylitis	0.000119	0.000258	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000118	0.000257	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-C—ankylosing spondylitis	0.000118	0.000256	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000117	0.000255	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL1A—ankylosing spondylitis	0.000117	0.000253	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-C—ankylosing spondylitis	0.000116	0.000253	CbGpPWpGaD
Crizotinib—TBK1—Immune System—CD40LG—ankylosing spondylitis	0.000116	0.000252	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1R2—ankylosing spondylitis	0.000116	0.000251	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CD79A—ankylosing spondylitis	0.000115	0.000249	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—TLR4—ankylosing spondylitis	0.000114	0.000248	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—TLR4—ankylosing spondylitis	0.000114	0.000248	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000113	0.000246	CbGpPWpGaD
Crizotinib—LCK—Immune System—CARD9—ankylosing spondylitis	0.000113	0.000246	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CD79A—ankylosing spondylitis	0.000113	0.000245	CbGpPWpGaD
Crizotinib—EPHA3—Developmental Biology—TNF—ankylosing spondylitis	0.000112	0.000244	CbGpPWpGaD
Crizotinib—EPHA5—Developmental Biology—TNF—ankylosing spondylitis	0.000112	0.000244	CbGpPWpGaD
Crizotinib—ABL2—Developmental Biology—TNF—ankylosing spondylitis	0.000112	0.000244	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000112	0.000243	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL1A—ankylosing spondylitis	0.000112	0.000243	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—CD40LG—ankylosing spondylitis	0.000111	0.000241	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-C—ankylosing spondylitis	0.00011	0.00024	CbGpPWpGaD
Crizotinib—BLK—Immune System—CD79A—ankylosing spondylitis	0.00011	0.00024	CbGpPWpGaD
Crizotinib—TBK1—Immune System—HLA-B—ankylosing spondylitis	0.00011	0.00024	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MMP3—ankylosing spondylitis	0.00011	0.00024	CbGpPWpGaD
Crizotinib—FGR—Immune System—CD79A—ankylosing spondylitis	0.00011	0.000239	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERAP1—ankylosing spondylitis	0.00011	0.000238	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000109	0.000237	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000109	0.000236	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000109	0.000236	CbGpPWpGaD
Crizotinib—EPHA8—Developmental Biology—TNF—ankylosing spondylitis	0.000108	0.000236	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HLA-C—ankylosing spondylitis	0.000108	0.000235	CbGpPWpGaD
Crizotinib—EPHB4—Developmental Biology—TNF—ankylosing spondylitis	0.000107	0.000233	CbGpPWpGaD
Crizotinib—LIMK2—Developmental Biology—TNF—ankylosing spondylitis	0.000107	0.000233	CbGpPWpGaD
Crizotinib—EPHA4—Developmental Biology—TNF—ankylosing spondylitis	0.000107	0.000233	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-C—ankylosing spondylitis	0.000107	0.000233	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—CRP—ankylosing spondylitis	0.000106	0.00023	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HLA-B—ankylosing spondylitis	0.000106	0.00023	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL1A—ankylosing spondylitis	0.000105	0.000229	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000105	0.000228	CbGpPWpGaD
Crizotinib—LIMK1—Developmental Biology—TNF—ankylosing spondylitis	0.000105	0.000228	CbGpPWpGaD
Crizotinib—JAK3—Immune System—CD40LG—ankylosing spondylitis	0.000105	0.000228	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—CRP—ankylosing spondylitis	0.000104	0.000227	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000104	0.000225	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1RN—ankylosing spondylitis	0.000102	0.000223	CbGpPWpGaD
Crizotinib—TBK1—Immune System—HLA-A—ankylosing spondylitis	0.000102	0.000222	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—TLR4—ankylosing spondylitis	0.000101	0.00022	CbGpPWpGaD
Crizotinib—JAK2—Disease—B3GNT2—ankylosing spondylitis	0.000101	0.00022	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000101	0.00022	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1RN—ankylosing spondylitis	0.000101	0.000219	CbGpPWpGaD
Crizotinib—EPHB6—Developmental Biology—TNF—ankylosing spondylitis	0.000101	0.000219	CbGpPWpGaD
Crizotinib—SRC—Immune System—CARD9—ankylosing spondylitis	0.0001	0.000218	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—TLR4—ankylosing spondylitis	0.0001	0.000217	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HLA-B—ankylosing spondylitis	9.97e-05	0.000217	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MMP3—ankylosing spondylitis	9.97e-05	0.000217	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—CRP—ankylosing spondylitis	9.9e-05	0.000215	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HLA-A—ankylosing spondylitis	9.79e-05	0.000213	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MMP3—ankylosing spondylitis	9.75e-05	0.000212	CbGpPWpGaD
Crizotinib—TBK1—Immune System—CRP—ankylosing spondylitis	9.74e-05	0.000212	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—CRP—ankylosing spondylitis	9.61e-05	0.000209	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1RN—ankylosing spondylitis	9.58e-05	0.000208	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—TLR4—ankylosing spondylitis	9.49e-05	0.000206	CbGpPWpGaD
Crizotinib—EPHA6—Developmental Biology—TNF—ankylosing spondylitis	9.48e-05	0.000206	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL1A—ankylosing spondylitis	9.39e-05	0.000204	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CD40LG—ankylosing spondylitis	9.34e-05	0.000203	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—CRP—ankylosing spondylitis	9.34e-05	0.000203	CbGpPWpGaD
Crizotinib—TBK1—Immune System—TLR4—ankylosing spondylitis	9.34e-05	0.000203	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1RN—ankylosing spondylitis	9.3e-05	0.000202	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL1A—ankylosing spondylitis	9.26e-05	0.000201	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HLA-A—ankylosing spondylitis	9.24e-05	0.000201	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—TLR4—ankylosing spondylitis	9.21e-05	0.0002	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CD40LG—ankylosing spondylitis	9.21e-05	0.0002	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	9.08e-05	0.000197	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL1A—ankylosing spondylitis	9.04e-05	0.000196	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PTGER4—ankylosing spondylitis	9.02e-05	0.000196	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL1A—ankylosing spondylitis	9.01e-05	0.000196	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD79A—ankylosing spondylitis	8.99e-05	0.000195	CbGpPWpGaD
Crizotinib—BLK—Immune System—CD40LG—ankylosing spondylitis	8.99e-05	0.000195	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—TLR4—ankylosing spondylitis	8.96e-05	0.000195	CbGpPWpGaD
Crizotinib—FGR—Immune System—CD40LG—ankylosing spondylitis	8.96e-05	0.000195	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD79A—ankylosing spondylitis	8.93e-05	0.000194	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PTGER4—ankylosing spondylitis	8.89e-05	0.000193	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.89e-05	0.000193	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HLA-B—ankylosing spondylitis	8.88e-05	0.000193	CbGpPWpGaD
Crizotinib—LCK—Disease—B3GNT2—ankylosing spondylitis	8.88e-05	0.000193	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD79A—ankylosing spondylitis	8.87e-05	0.000193	CbGpPWpGaD
Crizotinib—JAK3—Immune System—CRP—ankylosing spondylitis	8.81e-05	0.000191	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HLA-B—ankylosing spondylitis	8.8e-05	0.000191	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	8.76e-05	0.00019	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HLA-B—ankylosing spondylitis	8.76e-05	0.00019	CbGpPWpGaD
Crizotinib—EPHA2—Developmental Biology—TNF—ankylosing spondylitis	8.74e-05	0.00019	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-C—ankylosing spondylitis	8.67e-05	0.000188	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-C—ankylosing spondylitis	8.63e-05	0.000188	CbGpPWpGaD
Crizotinib—BLK—Immune System—HLA-B—ankylosing spondylitis	8.55e-05	0.000186	CbGpPWpGaD
Crizotinib—FGR—Immune System—HLA-B—ankylosing spondylitis	8.52e-05	0.000185	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PTGER4—ankylosing spondylitis	8.51e-05	0.000185	CbGpPWpGaD
Crizotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.49e-05	0.000184	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	8.45e-05	0.000184	CbGpPWpGaD
Crizotinib—JAK3—Immune System—TLR4—ankylosing spondylitis	8.45e-05	0.000184	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD79A—ankylosing spondylitis	8.41e-05	0.000183	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PTGER4—ankylosing spondylitis	8.25e-05	0.000179	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.25e-05	0.000179	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HLA-B—ankylosing spondylitis	8.24e-05	0.000179	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HLA-A—ankylosing spondylitis	8.23e-05	0.000179	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD79A—ankylosing spondylitis	8.16e-05	0.000177	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-C—ankylosing spondylitis	8.11e-05	0.000176	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HLA-A—ankylosing spondylitis	8.11e-05	0.000176	CbGpPWpGaD
Crizotinib—CDK7—Disease—HLA-A—ankylosing spondylitis	7.97e-05	0.000173	CbGpPWpGaD
Crizotinib—BLK—Immune System—HLA-A—ankylosing spondylitis	7.92e-05	0.000172	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD79A—ankylosing spondylitis	7.91e-05	0.000172	CbGpPWpGaD
Crizotinib—FGR—Immune System—HLA-A—ankylosing spondylitis	7.89e-05	0.000172	CbGpPWpGaD
Crizotinib—SRC—Disease—B3GNT2—ankylosing spondylitis	7.86e-05	0.000171	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CRP—ankylosing spondylitis	7.85e-05	0.000171	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.83e-05	0.00017	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—CRP—ankylosing spondylitis	7.78e-05	0.000169	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—MMP3—ankylosing spondylitis	7.75e-05	0.000168	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	7.74e-05	0.000168	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CRP—ankylosing spondylitis	7.74e-05	0.000168	CbGpPWpGaD
Crizotinib—BLK—Immune System—CRP—ankylosing spondylitis	7.55e-05	0.000164	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1RN—ankylosing spondylitis	7.53e-05	0.000164	CbGpPWpGaD
Crizotinib—FGR—Immune System—CRP—ankylosing spondylitis	7.53e-05	0.000164	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—TLR4—ankylosing spondylitis	7.53e-05	0.000164	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1RN—ankylosing spondylitis	7.5e-05	0.000163	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—TLR4—ankylosing spondylitis	7.46e-05	0.000162	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	7.42e-05	0.000161	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—TLR4—ankylosing spondylitis	7.42e-05	0.000161	CbGpPWpGaD
Crizotinib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	7.42e-05	0.000161	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1A—ankylosing spondylitis	7.37e-05	0.00016	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD40LG—ankylosing spondylitis	7.33e-05	0.000159	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	7.28e-05	0.000158	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CRP—ankylosing spondylitis	7.28e-05	0.000158	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1A—ankylosing spondylitis	7.27e-05	0.000158	CbGpPWpGaD
Crizotinib—BLK—Immune System—TLR4—ankylosing spondylitis	7.24e-05	0.000157	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD40LG—ankylosing spondylitis	7.23e-05	0.000157	CbGpPWpGaD
Crizotinib—FGR—Immune System—TLR4—ankylosing spondylitis	7.22e-05	0.000157	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	7.21e-05	0.000157	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MMP3—ankylosing spondylitis	7.21e-05	0.000157	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-C—ankylosing spondylitis	7.11e-05	0.000154	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PTGER4—ankylosing spondylitis	7.08e-05	0.000154	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1RN—ankylosing spondylitis	7.05e-05	0.000153	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.98e-05	0.000152	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—TLR4—ankylosing spondylitis	6.98e-05	0.000152	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-B—ankylosing spondylitis	6.97e-05	0.000151	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.93e-05	0.000151	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1A—ankylosing spondylitis	6.9e-05	0.00015	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-B—ankylosing spondylitis	6.88e-05	0.000149	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD40LG—ankylosing spondylitis	6.86e-05	0.000149	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1A—ankylosing spondylitis	6.69e-05	0.000145	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD40LG—ankylosing spondylitis	6.66e-05	0.000145	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.62e-05	0.000144	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD79A—ankylosing spondylitis	6.61e-05	0.000144	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD79A—ankylosing spondylitis	6.58e-05	0.000143	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-B—ankylosing spondylitis	6.52e-05	0.000142	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-A—ankylosing spondylitis	6.46e-05	0.00014	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.45e-05	0.00014	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTGER4—ankylosing spondylitis	6.43e-05	0.00014	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP3—ankylosing spondylitis	6.42e-05	0.00014	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.42e-05	0.000139	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HLA-B—ankylosing spondylitis	6.39e-05	0.000139	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CRP—ankylosing spondylitis	6.38e-05	0.000139	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-A—ankylosing spondylitis	6.37e-05	0.000138	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-B—ankylosing spondylitis	6.33e-05	0.000138	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP3—ankylosing spondylitis	6.33e-05	0.000138	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-C—ankylosing spondylitis	6.29e-05	0.000137	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	6.19e-05	0.000134	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD79A—ankylosing spondylitis	6.19e-05	0.000134	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1RN—ankylosing spondylitis	6.17e-05	0.000134	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CRP—ankylosing spondylitis	6.16e-05	0.000134	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.13e-05	0.000133	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	6.11e-05	0.000133	CbGpPWpGaD
Crizotinib—YES1—Immune System—CRP—ankylosing spondylitis	6.08e-05	0.000132	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP3—ankylosing spondylitis	6.06e-05	0.000132	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-A—ankylosing spondylitis	6.04e-05	0.000131	CbGpPWpGaD
Crizotinib—PTK2—Immune System—TLR4—ankylosing spondylitis	5.91e-05	0.000128	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP3—ankylosing spondylitis	5.87e-05	0.000128	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—MMP3—ankylosing spondylitis	5.87e-05	0.000128	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-A—ankylosing spondylitis	5.87e-05	0.000127	CbGpPWpGaD
Crizotinib—YES1—Immune System—TLR4—ankylosing spondylitis	5.83e-05	0.000127	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CRP—ankylosing spondylitis	5.76e-05	0.000125	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.68e-05	0.000123	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CRP—ankylosing spondylitis	5.65e-05	0.000123	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CRP—ankylosing spondylitis	5.6e-05	0.000122	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—TLR4—ankylosing spondylitis	5.53e-05	0.00012	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1RN—ankylosing spondylitis	5.46e-05	0.000119	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—TNF—ankylosing spondylitis	5.42e-05	0.000118	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1A—ankylosing spondylitis	5.42e-05	0.000118	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD79A—ankylosing spondylitis	5.42e-05	0.000118	CbGpPWpGaD
Crizotinib—TYK2—Disease—HLA-A—ankylosing spondylitis	5.42e-05	0.000118	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—TLR4—ankylosing spondylitis	5.41e-05	0.000118	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1A—ankylosing spondylitis	5.4e-05	0.000117	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD40LG—ankylosing spondylitis	5.39e-05	0.000117	CbGpPWpGaD
Crizotinib—TYK2—Immune System—TLR4—ankylosing spondylitis	5.36e-05	0.000117	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD40LG—ankylosing spondylitis	5.36e-05	0.000117	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—TNF—ankylosing spondylitis	5.35e-05	0.000116	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTGER4—ankylosing spondylitis	5.21e-05	0.000113	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	5.16e-05	0.000112	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-B—ankylosing spondylitis	5.13e-05	0.000111	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-B—ankylosing spondylitis	5.1e-05	0.000111	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1A—ankylosing spondylitis	5.07e-05	0.00011	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD40LG—ankylosing spondylitis	5.04e-05	0.00011	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP3—ankylosing spondylitis	5.04e-05	0.00011	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP3—ankylosing spondylitis	4.97e-05	0.000108	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—TNF—ankylosing spondylitis	4.92e-05	0.000107	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTGER4—ankylosing spondylitis	4.87e-05	0.000106	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-B—ankylosing spondylitis	4.8e-05	0.000104	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD79A—ankylosing spondylitis	4.8e-05	0.000104	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-A—ankylosing spondylitis	4.75e-05	0.000103	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-A—ankylosing spondylitis	4.73e-05	0.000103	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP3—ankylosing spondylitis	4.71e-05	0.000102	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP3—ankylosing spondylitis	4.58e-05	9.95e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CRP—ankylosing spondylitis	4.53e-05	9.85e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CRP—ankylosing spondylitis	4.51e-05	9.8e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-A—ankylosing spondylitis	4.45e-05	9.66e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1A—ankylosing spondylitis	4.44e-05	9.66e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD40LG—ankylosing spondylitis	4.42e-05	9.6e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—TLR4—ankylosing spondylitis	4.34e-05	9.44e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—TLR4—ankylosing spondylitis	4.32e-05	9.4e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	4.27e-05	9.27e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CRP—ankylosing spondylitis	4.24e-05	9.22e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-B—ankylosing spondylitis	4.2e-05	9.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—HLA-A—ankylosing spondylitis	4.1e-05	8.92e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—TLR4—ankylosing spondylitis	4.07e-05	8.84e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—ankylosing spondylitis	3.99e-05	8.67e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	3.97e-05	8.63e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1A—ankylosing spondylitis	3.93e-05	8.55e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD40LG—ankylosing spondylitis	3.91e-05	8.5e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	3.9e-05	8.47e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-A—ankylosing spondylitis	3.89e-05	8.46e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTGER4—ankylosing spondylitis	3.78e-05	8.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—ankylosing spondylitis	3.73e-05	8.11e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-B—ankylosing spondylitis	3.72e-05	8.08e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CRP—ankylosing spondylitis	3.71e-05	8.07e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP3—ankylosing spondylitis	3.71e-05	8.05e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.66e-05	7.96e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HLA-A—ankylosing spondylitis	3.59e-05	7.81e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—TLR4—ankylosing spondylitis	3.56e-05	7.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP3—ankylosing spondylitis	3.47e-05	7.54e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-A—ankylosing spondylitis	3.45e-05	7.49e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CRP—ankylosing spondylitis	3.29e-05	7.15e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HLA-A—ankylosing spondylitis	3.18e-05	6.92e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—TLR4—ankylosing spondylitis	3.15e-05	6.85e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	3.04e-05	6.6e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—ankylosing spondylitis	2.89e-05	6.29e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP3—ankylosing spondylitis	2.69e-05	5.84e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.4e-05	5.22e-05	CbGpPWpGaD
